Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived

Bibliography

• HOFF PM, ANSARI R, BATIST G et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. I Clin. Oncol (2001) 19:2282–2292.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, TWELVES C, CASSIDY J et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study.' Clin. Oncol (2001) 19:4097–4106.
   Web of Science ®Google Scholar
• SALTZ LB, COX JV, BLANKE C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl. I Med. (2000) 343:905–914.
   PubMed Web of Science ®Google Scholar
• DOUILLARD JY, CUNNINGHAM D,ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041–1047.
   Google Scholar
• DE GRAM ONT A, EIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol (2000) 18:2938–2947.
   Google Scholar
• GOLDBERG RM, MORTON RF, SARGENT DJ et al: N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/ leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1009).
   Google Scholar
• COMELLA P, MASSIDDA B, FILIPPELLI G et al.: Biweekly oxaliplatin (OXA) or irinotecan (IRI) with high dose folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0103) randomized study. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1123).
   Google Scholar
• TOURNIGAND C, LOUVET C, QUINAUX E et al.: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a Phase III study. Proc. Am. Soc. Clin. Onc. (2001) 20 (Abstract 494).
   Google Scholar
• ROTHENBERG ML, OZA AM, BIGELOW RH et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. Clin. OncoL (2003) 21:2059–2069.
   Web of Science ®Google Scholar
• ••The only published, large, randomisedsecond-line therapy trial in the post-IFL/ FOLFIRI era, indicates a generally poor response rate in the second-line setting.
   Google Scholar
• ROTHENBERG ML, OZA AM, BURGER B et al.: Final results of a Phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1011).
   Google Scholar
• TAYLOR EC, KUHNT D, SHIH C et aL: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[442-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yflethyl]benzoyll-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem. (1992) 35:4450–4454.
   PubMed Web of Science ®Google Scholar
• VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Clin. Oncol (2003) 21:2636–2644.
   Web of Science ®Google Scholar
• SCAGLIOTTI GV, SHIN DM, KINDLER HL et al.: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. Clin. Oncol. (2003) 21:1556–1561.
   Web of Science ®Google Scholar
• NIYIKIZA C, BAKER SD, SEITZ DE et al.: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer. Ther. (2002) 1:545–552.
   PubMed Web of Science ®Google Scholar
• RINALDI DA, BURRIS HA, DORR FA et al.: Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. Clin. Oncol (1995) 13:2842–2850.
   Web of Science ®Google Scholar
• JOHN W, PICUS J, BLANKE CD et al:Activity of multitargeted antifolate (pemetrexed disodium,LY231514) in patients with advanced colorectal carcinoma: results from a Phase II study. Cancer (2000) 88: 1807-1813.
   Google Scholar
• RAYMOND E, LOUVET C, TOURNIGAND C et al.: Pemetrexed disodium combined with oxaliplatin, 5N38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Int. I. Oncol (2002) 21:361–367.
   PubMed Web of Science ®Google Scholar
• ATKINS JN, JACOBS S, WIEAND S et al.: Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a Phase II trial of the NSABP foundation research program. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1108).
   Google Scholar
• KROENING H, HOCHSTER H, GROTHEY A et al.: Pemetrexed and irinotecan as second-line therapy for locally advanced or metastatic colorectal cancer: A Phase I dose escalation study. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1459).
   Google Scholar
• LINN SC, GIACCONE G: MDR1/ P-glycoprotein expression in colorectal cancer. Ear: J. Cancer (1995) 31A:1291–1294.
   Google Scholar
• BOLLAG DM, MCQUENEY PA, ZHU J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol- like mechanism of action. Cancer Res. (1995) 55:2325–2333.
   PubMed Web of Science ®Google Scholar
• LEE FY, BORZILLERI R, FAIRCHILD CR et al: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. (2001) 7:1429–1437.
   PubMed Web of Science ®Google Scholar
• ROTHERMEL J, WARTMANN M, CHEN T, HOHNEKER J: EP0906 (epothilone B): a promising novel microtubule stabilizer. Semin. Oncol (2003) 30:51–55.
   PubMed Web of Science ®Google Scholar
• ENG C, KINDLER HL, SKOOG L et al: The epothilone analogue, BMS-247550, in patients (pts) with advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1134).
   Google Scholar
• POPLIN E, MOORE M, O'DWYER P et al.: Safety and efficacy of EP0906 in patients with advanced colorectal cancer: A review of 2 Phase II trials. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1135).
   Google Scholar
• MEKHAIL T, CHUNG C, HOLDEN S et al.: Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 515).
   Google Scholar
• YOSHINARI T, OHKUBO M, FUKASAWA K et al.: Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. (1999) 59:4271–4275.
   PubMed Web of Science ®Google Scholar
• PECK R: Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc. Am. Soc. Clin. Onc. (2000) 19 (Abstract 767).
   Google Scholar
• LEWIS L, PEREZ R, PETROS W et al: a Phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule. Proc. Am. Soc. Clin. Onc. (2000) 19 (Abstract 688).
   Google Scholar
• YAMADA Y, YAMAMOTO N, SHIM OYAMA T et al.: Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc. Am. Soc. Clin. Onc. (2002) 21 (Abstract 385).
   Google Scholar
• NAHUM K, SHIBA D, PADAVANIJA P et al.: Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-naïve metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1099).
   Google Scholar
• RODRIGUEZ GI, JONES RE, ORENBERG EK, STOLTZ ML, BROOKS DJ: Phase I clinical trials of tezacitabine RE)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors. Clin. Cancer Res. (2002) 8:2828–2834.
   PubMed Web of Science ®Google Scholar
• BROOKS DJ, COX J, BERMAN BS et al:Phase II study of tezacitabine in subjects with advanced/recurrent colorectal cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1 1 22).
   Google Scholar
• FERNANDO NH, HURWITZ HI: Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin. °flea (2003) 30:39–50.
   Google Scholar
• •Comprehensive review of angiogenesis inhibition.
   Google Scholar
• WARREN RS, YUAN H, MATLI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.j Clin. Invest. (1995) 95: 1789-1797.
   Google Scholar
• •Important predinical bevacizumab work (with good figures).
   Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. " Clin. °flea (2003) 21:60–65.
   Web of Science ®Google Scholar
• HILLAN KJ, KOEPPEN HKW, TOBIN P et al.: The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 766).
   Google Scholar
• JOHNSON DH, DEVORE R, KABBINAVAR F et al: Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Soc. Clin. Onc. (2001) 20 (Abstract 1256).
   Google Scholar
• HURWITZ H, FEHRENBACHER L, CART WRIGHT T et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 3646).
   Google Scholar
• MARX J: Angiogenesis. A boost for tumorstarvation. Science (2003) 301:452–454.
   Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HERZ for metastatic breast cancer that overexpresses HERZ. N Engl. I Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• MENDELSON J: Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. (2000) 6:747–753.
   PubMed Web of Science ®Google Scholar
• •An excellent review of many aspects of EGFR inhibition.
   Google Scholar
• SCHREIBER AB, WINKLER ME, DERYNCK R: Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science (1986) 232:1250–1253.
   PubMed Web of Science ®Google Scholar
• NEAL DE, MARSH C, BENNETT MK et al.: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 1:366–368.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN NS, ARMIN M: Epidermal growth factor receptor54. immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV Colon Adenocarcinoma: implications for a standardized scoring system. Cancer (2001) 92:1331–1346.
   Google Scholar
• CHRISTEN RD, HOM DK, PORTER DC et al.: Epidermal growth factor regulates the M vitro sensitivity of human ovarian carcinoma cells to cisplatin. Clin. Invest. (1990) 86:1632–1640.
   Google Scholar
• FAN Z, BASELGA J, MASUI H, MENDELSOHN J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cir- diamminedichloroplatinum on well56.established A431 cell xenografts. Cancer Res. (1993) 53:4637–4642.
   Google Scholar
• LADEROUTE KR, AUSSERER WA, KNAPP AM, GRANT TD, SUTHERLAND RIVI: Epidermal growth factor modifies cell cycle control in A43157.human squamous carcinoma cells damaged by ionizing radiation. Cancer Res. (1994) 54:1407–1411.
   PubMed Web of Science ®Google Scholar
• WOLLMAN R, YAHALOM J, MAXY R, PINTO J, FUKS Z: Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells M vitro. Int. j Radiat. Oncol Biol. Phys. (1994) 30:91–98.
   PubMed Web of Science ®Google Scholar
• WAKSAL HW: Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev (1999) 18:427–436.
   PubMed Web of Science ®Google Scholar
• SALTZ L, RUBIN M, HOCHSTER H et al.: Cetwdmab (IMC-C2 25) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Proc. Am. Soc. Clin. Onc. (2001) 20 (Abstract 7).
   Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetwdmab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1012).
   Google Scholar
• SALTZ L, KIES M, ABBRUZZESE JL, AZARNIA N, NEEDLE M: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 817).
   Google Scholar
• YANG XD, JIA XC, CORVALAN JR, WANG P, DAVIS CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Grit. Rev Oncol Hematol (2001) 38:17–23.
   PubMed Web of Science ®Google Scholar
• TABERNERO J, ROJO F, JIMENE E et al.: A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (qlw), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD7 200 0, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc. AM. Soc. Clin. Onc. (2003) 22 (Abstract 770).
   Google Scholar
• FUKUOKA M, YANO S, GIACC ONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol (2003) 21:2237–2246.
   Google Scholar
• BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Omni (2002) 20:4292–4302.
   PubMed Web of Science ®Google Scholar
• • Gefitinib trial which includes colorectal cancer patients (no responses in this group).
   Google Scholar
• OZA AM, TOWNSLEY LL, SIUP, MAJOR D: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 785).
   Google Scholar
• SPECTOR N, RAEFSKY E, HURWITZ H et al.: Safety, clinical efficacy, and biologic assessments from EGF10004: A randomized Phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 772).
   Google Scholar
• BELANGER M, JONES CM, GERMOND C, BERGER MS: A Phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU5-FU in combination with irinotecan and/or oxaliplatin. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 978).
   Google Scholar
• SLICHENMYER WJ, ELLIOTT WL, FRY DW: CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol. (2001) 28:80–85.
   PubMed Web of Science ®Google Scholar
• WATERHOUSE DM, RINEHART J, ADJEI AA et al.: A Phase II study of an oral MEK inhibitor, CI-1040, in patients with advanced nonsmall-cell lung, breast, colon, or pancreatic cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 816).
   Google Scholar
• BHATNAGAR A, CARMICHAEL J, COSGRIFF T et al.: A randomized, double-blind, placebo controlled Phase III study of monoclonal antibody 3H1 plus 5-fluorouracil (5-FINleucovorin (LV) in stage IV colorectal carcinoma. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1041).
   Google Scholar
• WANG CY, CUSACK JC Jr., LIU R, BALDWIN AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat.. Med. (1999) 5:412–417.
   Google Scholar
• •Preclinical basis for use of proteasome inhibitors as chemosensitising agents.
   Google Scholar
• CUSACK JC Jr, LIU R, HOUSTON M et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. (2001) 61:3535–3540.
   PubMed Web of Science ®Google Scholar
• DREVS J, MROSS K, MEDINGE M et al.: Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1142).
   Google Scholar
• STEWARD WP, THOMAS AL, MORGAN B et al.: Extended Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ ZK 222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/ leucovorin as first line treatment for metastatic colorectal cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1098).
   Google Scholar
• TRARBACH T, SCHLEUCHER N, RIEDEL U et al: Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with irinotecan/ 5-fluorouracil/leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Onc. (2003) 22 (Abstract 1144).
   Google Scholar
• ELLIS LM: A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am. Surg. (2003) 69:3–10.
   PubMed Web of Science ®Google Scholar
• BERGERS G, SONG S, MEYER-MORSE N, BERGSLAND E, HANAHAN D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Invest. (2003) 111:1287–1295.
   Google Scholar